UPCC 24223: AIRPanc - A Phase 2 , Open-Label, Multicenter, Randomized Study Evaluating neoadjuvant therapy targeting the Adenosine immunosuppressive pathway in combination with Immune checkpoint blockade and Radiation Therapy in Patients with advanced
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
Please refer to Protocol Section 2 (Study Objectives). Please refer to Protocol Section 15.1 (Study Design/Endpoints). Please refer to Protocol Section 15.1 (Study Design/Endpoints).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 855023
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
